Skip to main content Accessibility help
×
Home

MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses

  • Sarah A. Morrow (a1), Lynn McEwan (a1), Katayoun Alikhani (a2), Christopher Hyson (a1) and Marcelo Kremenchutzky (a1)...

Abstract

Background:

Multiple Sclerosis is characterized by relapses separated by periods of relative quiescence. High dose intravenous corticosteroid pulses for three to five days is the current standard for the treatment of acute relapses, but recent evidence supports the use of equivalent doses of oral therapy as an alternative. The highest single dose preparation of oral prednisone is a 50mg tablet, requiring patients to take 25 tablets a day. Questions regarding compliance with this oral regimen have been raised.

Objectives:

To determine whether MS patients are complaint with 1250mg of oral prednisone daily for acute relapses.

Methods:

Between November 2008 and December 2009, all patients diagnosed with an acute relapse in the London (Ontario) MS clinic were prospectively identified. If treatment with oral prednisone was initiated, subjects were given a survey to be mailed anonymously to the clinic.

Results:

Sixtyeight MS relapses were diagnosed and treated with corticosteroids in 66 patients of which 60 (58 subjects) were treated with 1250mg prednisone. Fifty-three (91.4%) surveys were returned. The reported compliance rate was high at 94.3% (50/53) with only one patient reporting being unable to take all the required pills due to intolerance. Most subjects (43, 86.0%) encountered at least one side effect, most commonly insomnia, mood changes and increased appetite. Two thirds of subjects (69.8%) indicated a preference for oral medication for future relapses.

Conclusion:

High dose (1250mg) oral prednisone is an acceptable therapy to MS patients for the treatment of acute relapses with a high rate of compliance.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses
      Available formats
      ×

Copyright

Corresponding author

University of Western Ontario, LSHC-UH B10-118, 339 Windermere Rd, London, Ontario, N6G 1W8, Canada. Email: smorrow8@uwo.ca

References

Hide All
1Beck, CA, Metz, LM, Svenson, LW, Patten, SB.Regional variation of multiple sclerosis prevalence in Canada. Mult Scler. 2005;11: 51619.
2Murray, TJ.Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:5257.
3Confavreux, C, Vukusic, S, Moreau, T, Adeleine, P.Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:14308.
4Beck, RW, Cleary, PA, Backlund, JC.The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthal. 1994;101:17718.
5Sellebjerg, F, Barnes, D, Filippini, G, et al.EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12:93946.
6Goodin, DS, Frohman, EM, Garmany, GP Jr, et al.Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:16978.
7Metz, LM, Harris, CJ, Moore, A.MS patients’ choice of oral rather than IV steroid therapy results in savings to health care system. International Journal of MS Care (serial on the internet) 2000; March (cited 2010 Sept). Available at www.mscare.org
8Martinelli, V, Rocca, MA, Annovazzi, P, et al.A short-term randomized MRI study of high-dose oral vs. intravenous methylprednisolone in MS. Neurology. 2009;73:18428.
9Morrow, SA, Stoian, CA, Dmitrovic, J, Chan, SC, Metz, LM.The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:107980.
10Burton, JM, O’Connor, PW, Hohol, M, Beyene, J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009:CD006921.
11Metz, LM, Sabuda, D, Hilsden, RJ, Enns, R, Meddings, JB.Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology. 1999;53:20936.
12Beck, RW, Cleary, PA, Anderson, MM Jr., et al.A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:5818.
13Trobe, JD, Sieving, PC, Guire, KE, Fendrick, AM.The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1999;106:204753.
14Tse, FL, Welling, PG.Relative bioavailability of prednisone and prednisolone in man. J Pharm Pharmacol. 1979;31:4923.
15Morrow, SA, Metz, LM, Kremenchutzky, M.High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci. 2009;36:21315.
16Goff, DC, Hill, M, Freudenreich, O.Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2011;72:e13.
17Katon, WJ.Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13:723.
18World Health Organization (WHO). Adherence to long-term therapies. Evidence for action. 2003. Available at http://whqlibdoc.who.int/publications/2003/9241545992.pdf
19Hohl, CM, Abu-Laban, RB, Brubacher, JR, et al.Adherence to emergency department discharge prescriptions. CJEM 2009;11: 1318.
20Llor, C, Hernandez, S, Sierra, N, Moragas, A, Hernandez, M, Bayona, C.Association between use of rapid antigen detection tests and adherence to antibiotics in suspected streptococcal pharyngitis. Scand J Prim Health Care. 2010;28:1217.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed